Discover our Portfolio

The company Diaccurate, founded in December 2012, aims at developing new treatments to fight HIV infection. Diaccurate has obtained a worldwide and exclusive patent license from the Pasteur Institute. The treatment under development in the field of HIV is based on a major innovation which targets a protein “RIF” responsible for the immunological disease (inactivated CD4 T lymphocytes) observed in AIDS. Clinical trials are expected to begin in 2018.

Contact Truffle Capital

3 + 12 =

[sg_popup id=2]
5 Rue de la Baume, 75008 Paris, France Tel: +33 1 82 28 46 00



Truffle Capital

Truffle Capital

5 Rue de la Baume 75008 Paris France
Tel: +33 1 82 28 46 00

© 2018 Truffle Capital

Truffle Capital 2018

Social Networks